Shineco Stock Price, News & Analysis

Shineco, Inc. (NASDAQ: SISI) recently announced that its Cardiac 5-Minute Test has successfully passed quality inspection by China's NMPA, a significant milestone for its marketing in China. This test, developed by Shineco's subsidiary Biowin, is designed to quickly detect early-stage myocardial infarction, providing results in under 5 minutes, compared to over 20 minutes for existing tests. The NMPA's thorough evaluation focused on sensitivity, specificity, accuracy, and stability. Shineco aims to leverage this breakthrough in the Point-of-Care Testing market, which has a global potential of $3.5 billion.

Shineco, Inc. (NASDAQ: SISI) has announced a non-binding framework agreement to acquire 80% equity interests in Dream Partner Limited for an estimated $40 million. This acquisition targets Chongqing Wintus Group, a producer of antiviral silk fabric materials, to enhance Shineco's portfolio in the medical and healthcare sectors. The LOI is contingent upon shareholder approval and due diligence, which includes a third-party audit. Shineco's CEO highlighted potential synergies with previous acquisitions, aiming to create a vertically integrated R&D and production platform.

Shineco, Inc. (NASDAQ: SISI) announced that its affiliate, Changzhou Biowin Pharmaceutical Co., Ltd., received a Prior Approval Supplement from the Jiangsu Medical Products Administration for its 'Cardiac 5-minute Test'. This rapid diagnostic test detects key cardiac markers, aiming to improve the clinical diagnosis of acute myocardial infarction and reduce diagnosis time to under 10 minutes. This innovative product targets a global market worth over $3.5 billion and has significant potential in enhancing patient outcomes, especially in critical cardiovascular cases.

Shineco, Inc. (SISI) announced a significant advancement with the granting of a patent and FDA marketing approval for its in-situ fecal specimen sampling device. This innovative product simplifies stool sample collection with a design that enhances privacy and reduces contamination risk. It was recently showcased at MEDICA 2022, attracting attention from industry professionals. The device's features include a fingertip swab and unidirectional inlet, eliminating the need for traditional collection containers. Shineco aims to optimize stool collection for clinical tests, enhancing both convenience for patients and safety for laboratory staff.

Shineco, Inc. (SISI) announced its controlling affiliate, Changzhou Biowin Pharmaceutical Co., Ltd. (CBP), participated in MEDICA 2022 in Germany, showcasing innovative in vitro diagnostic products. Dr. Marvin Liu, Chairman of CBP, highlighted the success of introducing their COVID-19 home self-test, monkeypox testing products, and a leading stool sampling device. The presence at such a prestigious event is expected to enhance global awareness of CBP's technologies and foster partnerships, supporting the company's mission to deliver top-notch diagnostic solutions and create shareholder value.

On October 21, 2022, Shineco (NASDAQ: SISI) announced its acquisition of 51% of Changzhou Biowin Pharmaceutical Co., Ltd. for over $10 million. This strategic move aims to enter the Point-of-Care Testing (POCT) industry, which has seen a compound growth rate of 26%. CBP specializes in in-vitro diagnostics and has developed various rapid diagnostic products, particularly in high-demand areas like COVID-19 and Monkeypox. The deal is expected to enhance Shineco's market position and accelerate product development.

Shineco (NASDAQ: SISI) announced the appointment of Aamir Ali Quraishi as an Independent Director on August 17, 2022, succeeding Yanzeng An. Mr. Quraishi brings over 25 years of investment banking experience across Europe, Asia, and the Middle East, having completed over USD 20 billion in transactions. He has held leadership roles in various financial institutions, including Teneo Capital LLC. CEO Jennifer Zhan expressed gratitude towards Mr. An and optimism for Mr. Quraishi's contribution to Shineco's strategic growth.